专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090252751A1 Immune adjuvant comprising ubiquinone 审中-公开
标题翻译：包含泛醌的免疫佐剂
公开(公告)号：US20090252751A1
公开(公告)日：2009-10-08
申请号：US12213947
申请日：2008-06-26
申请人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
发明人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
IPC分类号： A61K39/00 , C07C49/603 , A61P31/00
CPC分类号： A61K39/39 , A61K2039/55511 , A61K2039/57 , C07C50/28
摘要： This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising a ubiquinone represented by formula (I), and a vaccine composition comprising the ubiquinone represented by formula (I):
摘要翻译：本发明涉及一种免疫佐剂，其具有优异的抗体产生增强功能并且是高度安全的，以及包含免疫佐剂的疫苗组合物。更具体地，本发明涉及包含由式（I）表示的泛醌的免疫佐剂和包含由式（I）表示的泛醌的疫苗组合物：

2. 发明授权

US09701739B2 Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof 有权
公开(公告)号：US09701739B2
公开(公告)日：2017-07-11
申请号：US13817714
申请日：2011-08-19
申请人： Shuji Sato , Takeshi Goto , Shigeru Goto , Toshiaki Nakano , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada , Kenji Mori , Takamitsu Miyagi
发明人： Shuji Sato , Takeshi Goto , Shigeru Goto , Toshiaki Nakano , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada , Kenji Mori , Takamitsu Miyagi
IPC分类号： A61K39/395 , C07K16/18 , C07K7/08
CPC分类号： C07K16/18 , A61K39/39541 , C07K7/08 , C07K2317/34
摘要： The present invention relates to a monoclonal antibody having excellent immunosuppressive activity or an antigen binding fragment thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, which binds to a peptide consisting an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO: 1) or a conjugate of the peptide and a pharmaceutically acceptable carrier, the monoclonal antibody or an antigen binding fragment thereof having a higher binding affinity for core histone than for histone H1.

3. 发明申请

US20140010815A1 MONOCLONAL ANTIBODY HAVING IMMUNOSUPPRESSIVE ACTIVITY OR ANTIGEN BINDING FRAGMENT THEREOF 有权
标题翻译：具有免疫抑制活性的单克隆抗体或其抗体结合片段
公开(公告)号：US20140010815A1
公开(公告)日：2014-01-09
申请号：US13817714
申请日：2011-08-19
申请人： Shuji Sato , Takeshi Goto , Shigeru Goto , Toshiaki Nakano , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada , Kenji Mori , Takamitsu Miyagi
发明人： Shuji Sato , Takeshi Goto , Shigeru Goto , Toshiaki Nakano , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada , Kenji Mori , Takamitsu Miyagi
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K39/39541 , C07K7/08 , C07K2317/34
摘要： The present invention relates to a monoclonal antibody having excellent immunosuppressive activity or an antigen binding fragment thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, which binds to a peptide consisting an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO: 1) or a conjugate of the peptide and a pharmaceutically acceptable carrier, the monoclonal antibody or an antigen binding fragment thereof having a higher binding affinity for core histone than for histone H1.
摘要翻译：本发明涉及具有优异免疫抑制活性的单克隆抗体或其抗原结合片段。更具体地，本发明涉及与由SSVLYGGPPSAA（SEQ ID NO：1）表示的氨基酸序列或肽与药学上可接受的载体的缀合物组成的肽结合的单克隆抗体或其抗原结合片段，对于核心组蛋白具有比组蛋白H1更高的结合亲和力的单克隆抗体或其抗原结合片段。

4. 发明申请

US20120128706A1 IMMUNE ADJUVANT COMPRISING ATP 审中-公开
标题翻译：免疫补充剂包含ATP
公开(公告)号：US20120128706A1
公开(公告)日：2012-05-24
申请号：US13316800
申请日：2011-12-12
申请人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
发明人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
IPC分类号： A61K39/39 , A61P37/04
CPC分类号： A61K39/39 , A61K2039/55511 , A61K2039/57 , A61K2039/6081
摘要： This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising ATP or its pharmaceutically acceptable salt, its solvate, or its derivative having a physiological function as an active ingredient, and a vaccine composition comprising the immunoadjuvant.
摘要翻译：本发明涉及一种免疫佐剂，其具有优异的抗体产生增强功能并且是高度安全的，以及包含免疫佐剂的疫苗组合物。更具体地，本发明涉及包含具有作为活性成分的生理功能的ATP或其药学上可接受的盐，其溶剂合物或其衍生物的免疫佐剂和包含免疫佐剂的疫苗组合物。

5. 发明申请

US20090081247A1 Immune adjuvant comprising ATP 审中-公开
标题翻译：包含ATP的免疫佐剂
公开(公告)号：US20090081247A1
公开(公告)日：2009-03-26
申请号：US12213874
申请日：2008-06-25
申请人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
发明人： Shuji Sato , Takeshi Goto , Naoya Ohmori , Kueichen Chiang , Yayoi Shimada
IPC分类号： A61K39/02 , A61K39/00 , A61K47/06 , A61P37/00 , A61P37/06
CPC分类号： A61K39/39 , A61K2039/55511 , A61K2039/57 , A61K2039/6081
摘要： This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising ATP or its pharmaceutically acceptable salt, its solvate, or its derivative having a physiological function as an active ingredient, and a vaccine composition comprising the immunoadjuvant.
摘要翻译：本发明涉及一种免疫佐剂，其具有优异的抗体产生增强功能并且是高度安全的，以及包含免疫佐剂的疫苗组合物。更具体地，本发明涉及包含具有作为活性成分的生理功能的ATP或其药学上可接受的盐，其溶剂合物或其衍生物的免疫佐剂和包含免疫佐剂的疫苗组合物。

6. 发明申请

US20100324469A1 DRUG PRODUCT, A METHOD OF ADMINISTRATING A VACCINE USING THE DRUG PRODUCT, AND AN APPARATUS FOR IONTOPHORESIS 审中-公开
标题翻译：药物产品，使用药物产品的疫苗管理方法和用于静脉注射的装置
公开(公告)号：US20100324469A1
公开(公告)日：2010-12-23
申请号：US12681508
申请日：2008-10-03
申请人： Kenji Mori , Takamitsu Miyagi , Yayoi Shimada , Kuei-Chen Chiang , Naoya Ohmori , Takeshi Goto , Shuji Sato
发明人： Kenji Mori , Takamitsu Miyagi , Yayoi Shimada , Kuei-Chen Chiang , Naoya Ohmori , Takeshi Goto , Shuji Sato
IPC分类号： A61N1/30
CPC分类号： A61N1/0448 , A61K39/00 , A61K2039/53 , A61K2039/54 , A61N1/0436 , A61N1/0444 , A61N1/30 , A61N1/325
摘要： It is an object of the present invention to provide a method and an apparatus capable of noninvasively administrating vaccine through the skin, and thereby making the immune response activate. A drug product according to the present invention is characterized in that the drug product has a support medium, an electrode formed on the support medium and protected partly by an insulating material for avoiding a direct cutaneous contact, a vaccine containing layer for containing a vaccine, wherein the vaccine is an antigen for inducing an immune suppression protein. A method of administrating a vaccine according to the present invention is characterized in that the vaccine is administrated by the iontophoresis using the drug product according to the drug product of the present invention as an electrode. An apparatus for the iontophoresis according to the present invention is characterized in that the drug product according to the present invention is used as an electrode.
摘要翻译：本发明的目的是提供一种能够通过皮肤无刺激地施用疫苗，从而使免疫反应活化的方法和装置。根据本发明的药物产品的特征在于药物产品具有载体介质，形成在载体介质上的电极，部分地被绝缘材料保护以避免直接皮肤接触，含有疫苗的疫苗含有层，其中所述疫苗是用于诱导免疫抑制蛋白的抗原。本发明疫苗的施用方法的特征在于，使用本发明药物的药物作为电极，通过离子电渗法给予疫苗。本发明的离子电渗疗法的特征在于，将本发明的药物用作电极。

7. 发明授权

US08187602B2 Anti-histone H1 monoclonal antibody and hybridoma for the production thereof 有权
标题翻译：抗组蛋白H1单克隆抗体和用于其生产的杂交瘤
公开(公告)号：US08187602B2
公开(公告)日：2012-05-29
申请号：US12762649
申请日：2010-04-19
申请人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
发明人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
IPC分类号： A61K39/00 , C12N5/12 , C12P21/08
CPC分类号： C07K16/18 , C07K7/08 , C07K14/47 , Y10S530/808 , Y10S530/809
摘要： The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.
摘要翻译：本发明公开了用于抑制，预测或诊断器官移植移植排斥反应的抗组蛋白H1单克隆抗体，其生产用杂交瘤和多肽。

8. 发明授权

US07964554B2 Polypeptide that binds anti-histone H1 antibody 有权
标题翻译：结合抗组蛋白H1抗体的多肽
公开(公告)号：US07964554B2
公开(公告)日：2011-06-21
申请号：US11661763
申请日：2005-09-05
申请人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
发明人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
IPC分类号： C07K7/08 , C07K17/02
CPC分类号： C07K16/18 , C07K7/08 , C07K14/47 , Y10S530/808 , Y10S530/809
摘要： The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.
摘要翻译：本发明公开了用于抑制，预测或诊断器官移植移植排斥反应的抗组蛋白H1单克隆抗体，其生产用杂交瘤和多肽。

9. 发明申请

US20080287352A1 Anti-Histone H1 Monoclonal Antibody and Hybridoma for the Production Thereof 有权
标题翻译：抗组蛋白H1单克隆抗体及其生产的杂交瘤
公开(公告)号：US20080287352A1
公开(公告)日：2008-11-20
申请号：US11661763
申请日：2005-09-05
申请人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
发明人： Takeshi Goto , Shuji Sato , Kazuhisa Ono , Seiko Shigeta , Seiji Kawamoto , Shigeru Goto
IPC分类号： A61K38/16 , C07K7/08 , A61K38/10 , A61P37/06 , G01N33/68
CPC分类号： C07K16/18 , C07K7/08 , C07K14/47 , Y10S530/808 , Y10S530/809
摘要： The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.
摘要翻译：本发明公开了用于抑制，预测或诊断器官移植移植排斥反应的抗组蛋白H1单克隆抗体，其生产用杂交瘤和多肽。

10. 发明申请

US20060188563A1 Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis 审中-公开
标题翻译：用于结肠输送的药用口服制剂，用于治疗结肠癌的药用口服制剂和用于治疗结肠炎的药用口服制剂
公开(公告)号：US20060188563A1
公开(公告)日：2006-08-24
申请号：US10550586
申请日：2003-03-27
申请人： Shuji Sato , Takeshi Goto , Norifumi Tanida , Tatsuya Meno , Takaaki Yoshinaga , Keishi Yonemura
发明人： Shuji Sato , Takeshi Goto , Norifumi Tanida , Tatsuya Meno , Takaaki Yoshinaga , Keishi Yonemura
IPC分类号： A61K9/48
CPC分类号： A61K31/513 , A61K9/2846 , A61K9/2886 , A61K31/58
摘要： A medicinal oral preparation to be delivered to the large intestine comprising a core containing a pharmacologically active ingredient, an inner layer containing one or more cationic polymers and an outer layer containing one or more anionic polymers whereby the core is coated, which is designed so that, in a disintegration test successively consisting of a vertical movement for 2 hours in a first solution of pH 1.2, a vertical movement for 2 hours in a second solution of pH 7.4 and a vertical movement in a third solution of pH 6.4, the average disintegration initiation point and the average disintegration completion point each falls within a period from 35 minutes to 130 minutes after starting the vertical movement in the third solution. Namely, a medicinal oral preparation to be delivered to the large intestine, a medicinal oral preparation for treating colon cancer and a medicinal oral preparation for treating colitis which would not disintegrate in the stomach or small intestine but begin to disintegrate after attaining the large intestine and surely complete the disintegration while remaining in the large intestine.
摘要翻译：一种药物口服制剂，其被输送至大肠，其包含含有药理活性成分的核心，含有一种或多种阳离子聚合物的内层和含有一种或多种阴离子聚合物的外层，其中所述芯被涂覆，其被设计为在依次由在pH1.2的第一溶液中垂直运动2小时，在pH 7.4的第二溶液中垂直运动2小时和在pH6.4的第三溶液中的垂直运动的崩解测试中，平均分解起始点和平均崩解完成点各自在第三溶液中开始垂直运动之后的35分钟至130分钟的时间段内。也就是说，要输送到大肠的药用口服制剂，用于治疗结肠癌的药物口服制剂和用于治疗不会在胃或小肠中分解而在达到大肠后开始分解的结肠炎的药物口服制剂，以及一定要在大肠的同时完成解体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式